PharmacoEconomics & Outcomes News 792, p14 - 2 Dec 2017 Introduction of biosimilar DMARDs cost saving to UK NHS The introduction of biosimilar disease-modifying antitrheumatic drugs (DMARDs) in the UK appears to be cost saving to the NHS, according to findings of a study published in BioDrugs. Data from the DEFINE database (March 2014–September 2017) were used to investigate the impact of introduction of infliximab biosimilars (Inflectra and Remsima) and etanercept biosimilar (Benepali) in UK NHS hospitals on the utilisation of biological DMARDs and the NHS budget. Cumulative cost savings associated with the introduction of infliximab and etanercept biosimilars ** totalled £38.8 million over a two-year period. Between March 2015 and February 2016, savings included £1 373 001 due to reduction in the price of branded infliximab (Remicade), and £877 422 and £415 549 due switching from Remicade to Inflectra and Remsima, respectively. Between March 2016 and February 2017, savings included £4 080 362 due to reduction in the price of Remicade, £2 714 366 and £5 938 132 due to switching to Inflectra and Remsima, respectively, £14 553 532 due to reduction in the price of branded etanercept (Enbrel), and £8 864 755 due to switching from Enbrel to Benepali. Monthly utilisation of abatacept, adalimumab, certolizumab pegol, golimumab and tocilizumab increased significantly, by between 0.48% and 3.06%. However, overall utilisation of etanercept did not change, and utilisation of infliximab decreased by 0.03% per month. The introduction of infliximab biosimilars significantly reduced the monthly utilisation of branded infliximab, and the introduction of etanercept biosimilar significantly reduced the monthly utilisation of branded etanercept (Enbrel). The introduction of DMARD biosimilars in UK hospitals "resulted in considerable cost savings to the NHS, with the branded products reducing their prices in response to the availability of less expensive biosimilars and competition between the biosimilars themselves," concluded the authors. "This suggests that when a biosimilar is available for a directly comparable branded molecule, price is the key influencing factor in its prescribing," they said. * National Health Service ** British pounds Aladul MI, et al. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs : 10 Nov 2017. Available from: URL: http://doi.org/10.1007/ s40259-017-0252-3 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera